Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Carintia Dorta Pérez


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


C. Dorta Pérez, M. Pulido Torrente, I.A. Castellano Carneiro, A.I. Martín Quesada, M. Morales González

Author affiliations

  • Medical Oncology, Hospital Universitario Nuestra Señora de Candelaria, 38010 - Santa Cruz de Tenerife/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5917


The increase in cancer survival and the development of new therapies has produced an increase in the hospital admissions through the Emergency Department (ED). To assess these patients and their outcome, we designed this study.


The records of patients admitted between July and November 2018 were studied. The following variables were registered: age, gender, comorbidities, type of cancer, stage, type and line of treatment, date of the last treatment, symptoms at admission, hospitalization length and outcome.


170 patients (83 men and 87 women) entered the study. The mean age was 61.4 years. The most frequent diagnoses were: lung (20%), breast (17.1%), colo-rectal (14.7%) and pancreatic (12.4%) cancers. Stages: I – II (15.5%), III (10.6%) and IV (75.9%). Type of therapy: chemotherapy (74.1%), immunotherapy (9.4%), targeted therapy (16.5%) and homone therapy (2.4%). Line of therapy: neo- or adjuvant (18%), first (46.6%), second (18%), third (9.9%) and fourth or subsequent (7.5%). The most frequent symptoms at admission were: fever (31.4%), dyspnoea (14.8%) and pain 14.8%). Thirty seven point six percent of admissions were because of tumour related complications, 34.7% because of toxicity and 27.1% because of non-leukopenic infection. The mean hospitalization length were 10.3 days. From the 170 patients, 32 died in the hospital and 13 within the first month after discharge. Tumour progression was the cause of death in 75% of the cases and the complications of therapy was in 18.2%. Seventy five percent were receiving a third or subsequent line of therapy and 66.5% received chemotherapy in the last month of life.


Despite all patients were managed according the ESMO and NCCN guidelines, there is a necessity to improve the clinical decisions, in order to improve the patients’ quality of life and the uses of hospital resources. The establishment of Clinical Decision Units in the ED, could help to this goal. Or perhaps there is a “missing link” between guidelines and the real clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Manuel Morales González.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.